Detail akcie Enanta Pharm online

Business Summary: Enanta Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of small molecule drugs with an emphasis on indications in virology and immunology. The Company’s clinical programs are focused on respiratory syncytial virus (RSV) and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, including receptor tyrosine kinase (KIT) and STAT6 inhibition. The Company has two clinical-stage product candidates for RSV, which are zelicapavir and EDP-323. Glecaprevir, a protease inhibitor discovered by the Company, is part of one of the treatment regimens for curing chronic hepatitis c virus (HCV) infection and is sold by AbbVie in various countries under the tradenames MAVYRET (U.S.) and MAVIRET (ex-U.S.) (glecaprevir/pibrentasvir). The Company also has development programs in virology for SARS-CoV-2 and Hepatitis B virus.
Financial Summary: BRIEF: For the six months ended 31 March 2025, Enanta Pharmaceuticals Inc revenues decreased 9% to $31.9M. Net loss decreased 30% to $44.9M. Revenues reflect United States segment decrease of 12% to $14.9M. Lower net loss reflects Pharmaceutical industry segment loss decrease of 29% to $48.1M, United States segment loss decrease of 25% to $24.5M. Basic Earnings per Share excluding Extraordinary Items increased from -$3.06 to -$2.11.